Tag: FRO

Blue Horseshoe Stocks: APP, CERS Recaps & More

American Apparel Inc. APP

It appears as if we brought APP back into the discussion yesterday at an opportune time, as the stock enjoyed a healthy intraday move on more than twice the 3-month average trading volume.

After briefly seeing a low of .63 the stock gradually built its way up to an afternoon high of .69, an increase of roughly 10%, and in the premarket this morning APP has already traded as high as .78. That pushes the overnight increase on APP to 24%

Yesterday we mentioned that breaking of the 200DMA of .74 was a key event that needed to take place and we’ve seen that happen this morning, so APP is certainly going to remain high on our watchlists as we head into week’s end.

Cerus Corp. CERS

CERS was included in yesterday’s extended watchlist, and made a solid move during the day’s session. From a low of 5.26 the stock made a run at a high of 5.94, a modest yet notable 13% increase.

It came on the heels of the announcement that the company had received the green light from the FDA on its product that limits the risk of infection-transmission in blood transfusions. We always like a good FDA-approval play so we will definitely be monitoring this play in coming sessions.

CONCORD, Calif.–(BUSINESS WIRE)–Cerus Corporation (CERS) today announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for plasma. The INTERCEPT plasma system is approved for ex vivo preparation of plasma in order to reduce the risk of transfusion-transmitted infection (TTI) when treating patients requiring therapeutic plasma transfusion. >> FULL PR

Eco Science Solutions, Inc. ESSI

We’ve still got ESSI on our radars, and wanted to remind our readers of this even as the stock has been trading in a tight channel between .20-.25 since we last took a look at it. The reason we still find ESSI attractive is that it boasts a tight share structure, and while we haven’t seen much in the way of volume, should that change, even the slightest amount of buying pressure could send ESSI flying.

From a business perspective, we’re also interested in the technology the company is working on, its innovative re-imagining on classic spark plug design. So despite not seeing much short-term activity, ESSI still has many of the hallmarks of a high-potential play that we’ll want to watch closely into the New Year.

We’ve drawn up a video on the current standing of the ESSI Chart, so take a look at that by clicking the graphic below:

If you missed our initial report on ESSI and its spark plug technology, go ahead and take a look now: ESSI Report

Extended Watchlist:
RAD, JNUG, EXXI, FRO, RGSE, AGEN, NQ, THCZ

Blue Horseshoe Stocks: TLM, HGSH & FRO Recaps

Talisman Energy, Inc. TLM

We began tracking TLM on Friday after noticing the stock coming up off of its recently-registered 52-week low, and on that day we observed a low of 4.17.

The stock made higher highs and higher lows yesterday following another inclusion in our morning report, making definite progress, but with a surprise buyout announcement early this morning the PPS has gone into overdrive.  The all-cash transaction is valued at $8 Billion, and has been unanimously approved on all sides.

CALGARY, ALBERTA–(Marketwired – Dec 16, 2014) – Talisman Energy Inc. (TLM.TO)(TLM) is pleased to announce that it has entered into a definitive agreement (the “Arrangement Agreement”) with Repsol S.A. under which Repsol will acquire all of the outstanding common shares of Talisman for US$8.00 (C$9.33) per share in cash. >> FULL PR

The premarket high thus far today stands at 7.74, which marks an increase of 85% that we’ve witnessed in TLM over the course of just a few days. Congrats to anyone who caught our pre-emptive alert and was able to take advantage!

China HGS Real Estate, Inc. HGSH

Another winning call off of yesterday’s report was HGSH; the stock appeared in our extended watchlist, and went on to have quite a fruitful session. The stock would open and briefly touch a low of 4.63 before spending the rest of the day on the rise, culminating in an afternoon high of 5.96.

That solid intraday move came on more than 10 the 3-month average volume, and represented a highly respectable increase of 29%

Frontline Ltd. FRO

Despite seeing a gap-down in this morning’s pre-market on the heels of a debt-for-equity program announced by FRO, we did see a nice move out of the stock yesterday after including it in our last couple of newsletters. It made an intraday move from 2.53 to 2.95 (+17%).

We observed a low of 1.88 on Friday, meaning that yesterday’s high figured in as a two-day overall increase of 57%

BioLineRx Ltd. BLRX

BLRX also appeared in yesterday’s extended watchlist, and while it had a tough time getting going yesterday, the stock is up significantly in today’s premarket activity on the strength of a new PR so we’ll be sure to monitor the situation as the week progresses.

The company has signed an agreement with pharma-giant Novartis, under which Novartis has made an initial equity investment in BLRX of $10M for 12.8% of BLRX’s current shares outstanding. Read more about it in the following news announcement:

Blue Horseshoe Stocks: FRO, OPK, WLGC & More

Frontline, Ltd. FRO

At the beginning of this month when we first began looking at FRO, the stock was trading at a low of 1.33. It took barely a week for the stock to start inching its way up, and it has continued to do so up to the present.

By the time we re-flagged it in Friday’s morning report, it had already cracked the $2.00-mark, and we did mention that the level of momentum was primed to allow for further opportunities.

This morning FRO continues to push the envelope, setting a new high in premarket trading action. This morning’s top figure of 2.64 puts us just slightly short of double-bagger status, having shown us an increase of 98% from the lows we observed the week before last.

It can be argued that the bolstering of activity seen on FRO (and other shipping plays) is due to the continuing fall of oil prices which translates to savings at the pump.

Opko Health, Inc. OPK

OPK is catching our attention in the premarket as well, as a result of an agreement announced this morning with pharma-giant Pfizer to develop and commercialize one of Opko’s highly promising products which combats Growth Hormone deficiency. Peruse the following PR to find out more; the development certainly lands OPK a spot on our watchlist to kick off the week.

In instances like these where a play is sent through the roof on substantial news, we look for the resulting profit-taking to pull the stock back, where we wait to take advantage of a possible dip-and-rip scenario.

OPKO Health, Inc. (OPK) and Pfizer Inc. (PFE) announced today that they have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD)… hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. >> FULL PR

WordLogic Corp. WLGC

Speaking of significant news, WLGC forces its way into our vernacular this morning on the heels of the announcement that the company will be teaming up with energy-leviathan General Electric (GE) in order to “monetize specific patented intellectual property in General Electric’s portfolio.”

With such a high-profile bedfellow, WLGC will instantly gain new recognition, and it will be very interesting to see how that translates to the chart.

Notable Gainers from Friday’s Extended Watchlist

Oncothyreon, Inc. ONTY – Range: 1.69-2.05   Gain: 21%

Organovo Holdings, Inc. ONVO – Range: 5.82-6.50  Gain: 11%

Extended Watchlist:
TLM, SN, BLRX, KEG, HGSH, CPST

Blue Horseshoe Stocks: ISR, Bottom Plays & More

IsoRay, Inc. ISR

We first began tracking ISR back in early October as a potential bottom play, and just a few sessions subsequent to our first mention, we would witness a low of 1.22 (10/16).

It took just a couple of weeks for us to ride ISR to a 66% gain as it ran to a high of 2.03 at the end of October. It consolidated down from that level, and for the past month or so the stock has been trading channel between 1.50-1.70.

ISR is catching our attention once again this morning, as we picked up on a new update over the press wire regarding the company’s Cesium-131 low-dose radiation therapy for brain cancer sufferers (Learn More About Cesium-131).

The Barrow Neurological Institute conducted studies with 27 patients with several variations of brain cancer, and the company is reporting that there was no recurrence of the disease on the treated sites in 26 out of the 27 candidates, where other treatments had failed. >> Read PR

We’re going to be interested to see how the stock picks up trading following the holiday week, especially with such an encouraging piece of news out in the premarket. So far, the ISR has gone as high as 2.08 in preliminary trading this morning. We could be looking at a dip-and-scenario once the session commences; to remain interested we’ll want to see support hold at a minimum of 1.89 as that would mark a 50% retrace from the current premarket range.

Potential Bottom Plays

AEterna Zentaris, Inc. AEZS absolutely fell off a cliff back in early November, following FDA denial of a New Drug Application AEZS had submitted. The stock has spent the intervening time bottoming out, and it is now trading at all-time lows. This is exactly the sort of situation that sends us into “vulture-mode”, where we’re on the lookout for any signs of recovery after a stock has been hammered down.

Frontline, Ltd. FRO is a stock that is in the process of coming off of a recent bottom, and is showing signs of life here in today’s premarket, currently trading in the mid-1.30’s.

Extended Watchlist:
JNUG, GRPN, AG, ONNN

Blue Horseshoe Stocks: PBR, PTIE Updates, & More

Petroleo Brasiliero S.A. (Petrobras) PBR Options

Our long-time favorite options-trading target, PBR, after taking a significant beating over the past couple of weeks, finally found support in the 10.80’s and began to bounce back during yesterday’s session. It marked the lowest PPS we’ve witnessed since we first began watching this play. We’re also seeing a moderate gap-up in premarket trading this morning. We want to see it achieve higher lows and higher highs over the next few sessions to confirm the trend.

We’ve experienced many dips and rips with PBR over the roughly 7-month period we’ve been tracking it, and as we usually do in this situation, we’re going to attempt to take advantage of the recovery pattern we’re observing. For a specific idea, we want to radar the November 14th 12.00 Calls.

Pain Therapeutics, Inc. PTIE 

The huge gap down we noticed in the premarket yesterday is what drew us to include PTIE in our morning report. We mentioned that we’d monitor it for a eventual bounce and it came almost immediately. The stock saw a brief morning low of 1.61, and bounced back as high as 2.14 in the afternoon.

It marked a 33% intraday move, and intrigued us enough to want to continue watching as the week progresses.

The cause of the enormous gap-down was the nixing of an agreement the company had with Pfizer to develop and commercialize its Remoxy pain medication. It’s worth it to note that despite the huge setback, the stock came into this week with an analyst price target of 8.00/share.

Ascent Solar Technologies, Inc. ASTI

ASTI is one we’ve had an eye on for the past several weeks as it has searched out its own lows, and after reaching a bottom in the 1.40-range a couple of weeks ago, the stock has been making some nice strides to recover lost ground.

This morning the stock is gapping up over $2 on the heels of an early morning PR relating to a key milestone in a potentially lucrative Chinese joint venture.

Extended Watchlist:
DRYS, FRO, JNUG, WAVX, WMGIZ 

Get Our FREE Daily Reports!

SUBSCRIBE